KHK2866 + gemcitabine + carboplatin

KHK2866 + gemcitabine + carboplatin is a **combination therapy** under early clinical investigation for advanced cancers, specifically ovarian, fallopian tube, and primary peritoneal cancers[3][7]. KHK2866 is a recombinant, humanized, non-fucosylated monoclonal antibody that targets **heparin-binding epidermal growth factor-like growth factor (HB-EGF)**, aiming to reduce its biological activity to inhibit tumor growth[1][5]. Gemcitabine is an antimetabolite chemotherapeutic agent that is incorporated into DNA during replication, leading to cell death. Carboplatin is a platinum-based agent that crosslinks DNA, also resulting in tumor cell apoptosis. The combination seeks to enhance antitumor effects by leveraging targeted inhibition of HB-EGF together with DNA synthesis disruption and DNA crosslink damage from gemcitabine and carboplatin, respectively[3]. KHK2866's development was halted after phase 1 due to dose-limiting neuropsychiatric toxicity as monotherapy, though combinations were considered in trials[1][3].

Other names

heparin-binding epidermal growth factor-like growth factor antibody + gemcitabine + carboplatin